Investor Presentaiton

Diagnostics Overview -$10.8B TOTAL REVENUE 2022 Revenue By Mix Non- recurring Recurring BECKMAN COULTER Leica RADIOMETER® Cepheid. BIOSYSTEMS GLOBAL GROWTH DRIVERS • Penetration of molecular diagnostics By Geography By End Market • Point-of-care & decentralization of health care ROW Molecular Clinical HGM NA W. EU All financial metrics reflect FY 2022 results from continuing operations; all pie chart percentages are % of 2022 revenues. Pathology & Acute/ POC Skilled labor shortages & cost pressures necessitating automated solutions Improving standards of care in HGM Strong global brands with leading market positions 21 DANAHER

View entire presentation